Marshall Wace
ASMB icon

Marshall Wace’s Assembly Biosciences ASMB Stock Holding History

Marshall Wace’s Portfolio ASMB Stock Details ASMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$487K Sell
17,735
-145,665
-89% -$3.97M ﹤0.01% 2538
2026
Q1 		$4.53M Buy
163,400
+34,325
+27% +$979K ﹤0.01% 1352
2025
Q4 		$4.39M Buy
129,075
+43,860
+51% +$1.41M ﹤0.01% 1209
2025
Q3 		$2.18M Buy
+85,215
New +$1.87M ﹤0.01% 1567
2025
Q2 		– Sell
-18,040
Closed -$172K – 2685
2025
Q1 		$172K Buy
18,040
+3,217
+22% +$42.1K ﹤0.01% 2434
2024
Q4 		$234K Buy
14,823
+2,098
+16% +$33.8K ﹤0.01% 2308
2024
Q3 		$193K Buy
+12,725
New +$194K ﹤0.01% 2300
2020
Q2 		– Sell
-325
Closed -$58K – 1531
2020
Q1 		$58K Sell
325
-10,012
-97% -$2.15M ﹤0.01% 1403
2019
Q4 		$2.54M Buy
10,337
+6,302
+156% +$1.16M 0.02% 737
2019
Q3 		$476K Buy
4,035
+2,003
+99% +$303K ﹤0.01% 1118
2019
Q2 		$330K Sell
2,032
-16,287
-89% -$3.1M ﹤0.01% 1167
2019
Q1 		$4.33M Sell
18,319
-10,162
-36% -$2.57M 0.04% 511
2018
Q4 		$7.73M Buy
28,481
+3,297
+13% +$954K 0.08% 311
2018
Q3 		$11.2M Buy
+25,184
New +$11.8M 0.1% 282

Other funds holding ASMB

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $977M AUM 110.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Marshall Wace's ASMB Position: Q2 2026 in Review

Marshall Wace reduced its Assembly Biosciences (ASMB) stake by 89% in Q2 2026, selling an estimated $3.97M and leaving 17,735 shares worth $487K. The position accounts for ﹤0.01% of the portfolio, ranked #2538.

Marshall Wace first reported a position in ASMB in Q3 2018 and has held it in 14 quarters since. The position peaked at $11.2M in Q3 2018. 93 funds tracked by Wall St. Rank hold ASMB as of Q2 2026.

  • Marshall Wace held 17,735 shares of Assembly Biosciences worth $487K as of Q2 2026.
  • Marshall Wace sold 145,665 Assembly Biosciences shares in Q2 2026, an estimated $3.97M.
  • Assembly Biosciences made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #2538 holding.
  • Marshall Wace first reported a position in Assembly Biosciences in Q3 2018 and has held it in 14 quarters since.
  • Marshall Wace's Assembly Biosciences position peaked at $11.2M in Q3 2018.
  • 93 funds tracked by Wall St. Rank held Assembly Biosciences as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.